Dark Horse Consulting Group Inc.
Nathan Manley has a diverse work experience. Nathan currently serves as the Senior Principal, Head of Nonclinical at Dark Horse Consulting Group Inc., where they have been working since 2019. Prior to this, they held the positions of Principal and Senior Consultant at the same company. Additionally, Nathan worked as a Faculty member at San Jose State University starting in 2020. Before that, they were an Instructor at UCSC Extension Silicon Valley from 2018 to 2020. Nathan has also worked at Asterias Biotherapeutics as an Associate Director and Senior Scientist, specializing in neurobiology and preclinical development of stem cell-based therapies. Nathan has conducted research and made significant contributions in the field of neurological disease treatment during their Postdoctoral Scholar appointments at Stanford University School of Medicine and Stanford University.
Nathan Manley completed their education with a Ph.D. in Biological Sciences from Stanford University, where they were enrolled from 2003 to 2009. Prior to that, they obtained a Bachelor of Science with college honors in Cell & Molecular Biology from the University of Washington. Nathan attended the University of Washington from 1999 to 2003.
Dark Horse Consulting Group Inc.
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and enginnering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.